Low density lipoprotein receptor-related protein 1 expression correlates with cholesteryl ester accumulation in the myocardium of ischemic cardiomyopathy patients by Cal, Roi et al.
Cal et al. Journal of Translational Medicine 2012, 10:160
http://www.translational-medicine.com/content/10/1/160RESEARCH Open AccessLow density lipoprotein receptor-related protein
1 expression correlates with cholesteryl ester
accumulation in the myocardium of ischemic
cardiomyopathy patients
Roi Cal1, Oriol Juan-Babot1, Vicenç Brossa2, Santiago Roura3, Carolina Gálvez-Montón3, Manolo Portoles4,
Miguel Rivera4, Juan Cinca2, Lina Badimon1,5 and Vicenta Llorente-Cortés1*Abstract
Our hypothesis was that overexpression of certain lipoprotein receptors might be related to lipid accumulation in
the human ischemic myocardium. Intramyocardial lipid overload contributes to contractile dysfunction and
arrhythmias in cardiomyopathy. Thus, the purpose of this study was to assess the effect of hypercholesterolemic
LDL and hypertrigliceridemic VLDL dose on LRP1 expression in cardiomyocytes, as well as the potential correlation
between LRP1 expression and neutral lipid accumulation in the left ventricle tissue from ischemic cardiomyopathy
patients. Cell culture experiments include control and LRP1-deficient cardiomyocytes exposed to lipoproteins under
normoxic and hypoxic conditions. Explanted hearts from 18 ICM patients and eight non-diseased hearts (CNT) were
included. Low density lipoprotein receptor-related protein 1 (LRP1), very low density lipoprotein receptor (VLDLR)
and low density lipoprotein receptor (LDLR) expression was analyzed by real time PCR and Western blotting.
Cholesteryl ester (CE), triglyceride (TG) and free cholesterol (FC) content was assess by thin layer chromatography
following lipid extraction. Western blotting experiments showed that protein levels of LRP1, VLDLR and HIF-1α were
significantly upregulated in ischemic hearts. Immunohistochemistry and confocal microscopy analysis showed that
LRP1 and HIF-1α were upregulated in cardiomyocytes of ICM patients. In vitro studies showed that VLDL, LDL and
hypoxia exerted an upregulatory effect on LRP1 expression and that LRP1 played a major role in cholesteryl ester
accumulation from lipoproteins in cardiomyocytes. Myocardial CE accumulation strongly correlated with LRP1 levels
in ischemic hearts. Taken together, our results suggest that LRP1 upregulation is key for myocardial cholesterol ester
accumulation in ischemic human hearts and that LRP1 may be a target to prevent the deleterious effects of
myocardial cholesterol accumulation in ischemic cardiomyopathy.
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The ischemic condition caused by decreased coronary
flow is one of the most important factors leading to heart
failure. Under ischemic conditions the myocardium
undergos lipid accumulation in animal models [1-3] and
humans [4]. In the ischemic heart, lipid vacuoles have
been located in the periphery of the risk area [5,6]. While
some authors have proposed a cardioprotective role for* Correspondence: cllorente@csic-iccc.org
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reproduction in any medium, provided the orcytosolic lipids in the cardiomyocyte [7,8], others associ-
ate this phenomena to lipotoxicity [2,9]. In fact, it has
been consistently reported that intramyocardial lipid
overload significantly contributes to contractile dysfunc-
tion [10] and arrhythmias [11]. Recent work from our
group demonstrated that myocytes exposed to high very
low density lipoprotein (VLDL) doses depicts intracellu-
lar accumulation of neutral lipids, downregulation of
SERCA2 expression, reduction of calcium transient amp-
litude, and SR calcium loading. These effects were exa-
cerbated by submitting the cultured myocytes to an
hypoxic environment [12]. Remarkably, a high prevalence. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Cal et al. Journal of Translational Medicine 2012, 10:160 Page 2 of 11
http://www.translational-medicine.com/content/10/1/160of fat deposition has been found in areas of chronic myo-
cardial infarction in humans [4]. The patients with fat de-
position had larger infarctions, decreased wall thickening
and impaired endocardial wall motion [4].
It is known from several years ago that triglyceride
(TG)-rich lipoproteins (chylomicrons and VLDL) supply
both triglycerides and cholesteryl esters (CE) to the heart
[13-15]. At present, the lipoprotein receptors involved in
TG and/or cholesterol uptake by the cardiomyocyte re-
main largely unknown. Indeed, a basal expression of lipo-
protein receptors is essential to guarantee a correct
energetic supply for the heart since its inhibition causes a
marked decline in cardial mechanical function [15].
However, the upregulation of several lipoprotein recep-
tors, including very low density lipoprotein receptor
(VLDLR) [16] or low density lipoprotein receptor related
protein 1 (LRP1) [17], has been previously reported to in-
duce neutral lipid accumulation in cardiomyocytes under
ischemic conditions. Moreover, both VLDLR [16] and
LRP1 [17,18] share a HIF-1α-dependent mechanism of
transcriptional activation by hypoxia in cultured cells.
Our group has also shown that LRP1 expression and
cholesteryl esters levels are found upregulated in the is-
chemic myocardium of an in vivo porcine model of acute
myocardial infarction [17]. LRP1 is also upregulated by
extracellular matrix-aggregated LDL in cultured human
vascular smooth muscle cells and by hypercholesterol-
emia in the porcine vascular wall [19].
According to our previous work in this field, we
hypothesized that LRP1 may be upregulated by lipids in
cardiomyocytes playing a key role in the ischemia-
induced neutral lipid accumulation in human heart.
Thus, the purpose of this study was to assess the effect
of hypercholesterolemic LDL and hypertrigliceridemic
VLDL dose on LRP1 expression in cardiomyocytes, as
well as the potential correlation between LRP1 expres-
sion and neutral lipid accumulation in the left ventricle
tissue from patients with ischemic cardiomyopathy.Material and methods
Collection of human samples
A total of 18 explanted human hearts from ischemic car-
diomiopathy patients was collected and immediately pro-
cessed. In particular, these patients were undergoing
cardiac transplantation at Sant Pau Hospital, Barcelona
and La Fe Hospital, Valencia. Clinical data, electrocardio-
gram, Doppler echocardiography, hemodynamic studies,
and coronary angiography were available on all patients.
All patients were functionally classified according to the
New York Heart Association (NYHA) criteria, and were
receiving medical treatment according to the guidelines
of the European Society of Cardiology [20], with diuretics
90 %, angiotensin-converting enzyme inhibitors 87 %,β-blockers 50 %, aldosterone antagonists 70 %, digoxin
49 % and statins 80 %.
Eight non-diseased hearts were also obtained from
donors with neurological death caused by traffic acci-
dent. The hearts were initially considered for cardiac
transplantation but were subsequently deemed unsuit-
able for transplantation either because of blood type or
size incompatibility. All donors had normal LV function
and no history of myocardial disease or active infection.
Transmural samples were taken from the infarct
border zone, and were immediately stored at −80 °C.
The project was approved by the local Ethics Committee
(Biomedical Ethics Committee of “La Fe, Valencia” and
“Sant Pau, Barcelona”, Spain) and conducted in accord-
ance with the guidelines of the Declaration of Helsinki.
All patients gave written informed consent that was
obtained according to our institutional guidelines.
Tissue homogenization
Frozen ventricular tissues (25 mg) were pulverized using
a mortar and a pestle in liquid nitrogen. Sample were
then homogenized in TriPure isolation reagent (Roche
Molecular Biochemicals) for total RNA and protein ex-
traction according to manufacturer’s instructions.
HL-1 cardiomyocyte cell culture
The murine HL-1 cell line was generated by Dr. W.C.
Claycomb (Louisiana State University Medical Centre,
New Orleans, Louisiana, USA) and kindly provided by
Dr. U Rauch (Charité-Universitätmedizin Berlin). These
cells show cardiac characteristics similar to those of
adult cardiomyocytes. LRP1-deficient cardiomyocytes
were generated as previously described [17]. Control and
LRP1-deficient HL-1 cardiomyocytes were maintained
in Claycomb Medium (JRH Biosciences, Lenexa, KS,
USA) supplemented with 10 % fetal bovine serum (FBS)
(Invitrogen Corporation, Carlsbad, CA, USA), 100 μM
norepinephrine, 100 units/mL penicillin, 100 μg/mL
streptomycin, and L-Glutamine 2 mM (Sigma Chemical
Company, St. Louis, MO, USA) in plastic dishes, coated
with 12.5 μg/mL fibronectin and 0.02 % gelatin, in a 5 %
CO2 atmosphere at 37 °C.
VLDL and LDL preparation
Human VLDL (d1.019-d1.019 g/mL) and LDL (d1.009-
d1.063 g/mL) were obtained from pooled sera of normo-
cholesterolemic volunteers. VLDL and LDL preparations
were less than 24 hours old and without detectable levels
of endotoxin (Limulus Amebocyte Lysate test, Bio Whit-
taker). Aggregated LDL (agLDL) was prepared by vortex-
ing LDL in PBS at room temperature. The formation of
LDL aggregates was performed as previously described
[21-23]. The ultrastructure of agLDL obtained by vortex-
ing was similar to that of LDL modified by versican [22],
Table 1 Clinical and echocardiographic characteristics
from whom explanted ischemic hearts were obtained
ICM (n = 18)
Age (years) 54.53 ± 2.67
Gender male (%) 93 %
Prior hypertension (%) 46
Diabetes mellitus (%) 27
Obesity (%) 20
Total cholesterol (nmol/L) 3.90 ± 0.28
Perfusion abnormalities* (%) 67 %
Echo-Doppler study
Ejection fraction (%) 25.86 ± 1.80
Intraventricular septum in diastole (mm) 11.08 ± 0.47
Left ventricular posterior wall in diastole (mm) 9.67 ± 0.62
Left ventricular end-diastolic diameter (mm) 67.00 ± 2.45
Left ventricular end-systolic diameter (mm) 58.50 ± 3.94
Treatment (%)
Diuretics 90
Angiotensin-converting enzymes inhibitors 87
β-blockers 50
Aldosterone antagonist 70
Digoxin 49
Statins 80
ICM, ischemic cardiomyopahhy; *the patients with perfusion abnormalities
were considered those subjected to coronary interventions (i.e. by-pass,
angioplasty, stents and others).
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turing the arterial intima.
Exposure of cardiomyocytes to VLDL and LDL under
normoxic and hypoxic conditions
Cells were exposed to normoxia (21 % O2) in a Nirco
gas incubator with gas mixtures consisting of 74 %N2
and 5 % CO2 or to hypoxia (1 % O2) in a Hypoxic/An-
oxic Workstation: H35 (Don Whitley Scientific Ltd.)
with 94 %N2 and 5 % CO2. Lipoproteins were added
and maintained for the last 12 hours of exposure to nor-
moxic or hypoxic conditions (24 hours). Cells were then
harvested in TriPure Reagent (Roche) for PCR and
Western blot analysis or in NaOH 0.1 M for lipid extrac-
tion and thin layer chromatography.
RNA extraction and cDNA synthesis
Total RNA was extracted from fresh frozen tissue or
cultured HL-1 cardiomyocytes using TriPure isolation
reagent (Roche Molecular Biochemicals) and the RNeasy
mini kit (Qiagen, Hilden, Germany) according to manu-
facturer’s instructions. Extracted RNA was eluded in 25
μL of nucleases-free water. RNA yield and quality were
assessed by agarose electrophoresis and spectrophotom-
etry, and then stored at −80°C until was used. RNA was
digested with DNase I (Invitrogen). One μg of total RNA
was used for cDNA synthesis according to the protocol
provided with the HighCapacity cDNA Reverse Tran-
scription kit (Applied Biosystems, Foster City, CA,
USA). Recombinant RNasin Ribonuclease Inhibitor (Ap-
plied Biosystems) was added to prevent RNase-mediated
degradation. The cDNA was also stored at –20 C.
Gene expression analyses by RT-PCR
Gene expression analyses of LRP1, VLDLR, and LDLR
mRNA were performed at mRNA level by quantitative
real-time reverse transcriptase-polymerase chain reac-
tion (q-RT-PCR). Specific primer and fluorescent Taq-
Man probe for LRP1, VLDLR and LDLR were selected
within a list of predesigned assays (Assays-on-Demand
LRP1 (Hs00233999_m1), VLDLR (Hs01045922_m1) and
LDLR (Hs00181192_m1) (Applied Biosystems). 18srRNA
(4319413E) was used as a housekeeping gene. We mixed
5 μl of single-stranded cDNA (equivalent to 100 ng of
total RNA) with 1 μl of 20x TaqMan Gene Expression
Assays for each Assay-on-Demand, 10 μl of TaqMan
Universal PCR Master Mix, and 4 μl of nucleases-free
water. After gentle mixing, the mixture was transferred
into a real-time PCR microplate. The Real-time PCR
microplate was sealed, centrifuged, and then was placed
in the sample block of an Applied Biosystems 7300 Real
Time PCR System (Applied Biosystems). The thermal
cycling conditions were 2 min at 50°C and 10 min at
95°C, followed by 40 cycles of 15 s at 95°C and 1 minat 60°C. Expression levels were measured in triplicate.
The threshold cycle (Ct) values were normalized to the
housekeeping gene [17,18].
Western blotting
Total protein was extracted from fresh frozen tissue or
HL-1 cell cultures using TriPure isolation reagent
(Roche Molecular Biochemicals). Proteins were analyzed
by Western blot analysis as previously described [17,18].
Blots were incubated with monoclonal antibodies against
human LRP1 (β-chain, clone 8B8 RDI 61067), VLDLR
(Santa Cruz Biotechnology, Inc, D-17, sc-11823), HIF-1α
(Santa Cruz Biotechnology, H-206, sc-10790), LDLR
(Epitomics, EP1553Y, 1956–1), VEGF (Santa Cruz Bio-
technology, Inc, A2611, sc-152) and mouse monoclonal
anti-Troponin T (Thermo scientific MS-295). Equal pro-
tein loading in each lane was verified staining filters with
Pounceau and also by incubating blots with monoclonal
antibodies against β-actin (Abcam, ab8226).
Lipid extraction and semi-quantitative analysis of
cholesteryl ester, free cholesterol and triglyceride content
of cardiomyocytes and myocardium
HL-1 cardiomyocytes were exhaustively washed and
harvested in NaOH 0.1 M following the lipoprotein
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one portion of myocardial tissue (5 mg) was also
homogenized in NaOH 0.1 M. Lipids were extracted
as previously described [17,18] and CE, FC and TG
content was analyzed by thin layer chromatography.
The organic solvent was removed under an N2 stream,
the lipid extract redissolved in dichloromethometane
and one aliquot was partitioned by thin layer chroma-
tography (TLC). TLC was performed on silica G-24
plates. The different concentrations of standards (a mix-
ture of cholesterol, cholesterol palmitate, triglycerides,
diglycerides and monoglycerides) were applied to each
plate. The chromatographic developing solution was
heptane/diethylether/acetic acid (74:21:4, vol/vol/vol).
The spots corresponding to cholesteryl esters (CE), tri-
glycerides (TG) and free cholesterol (FC) were quantified
by densitometry against the standard curve of choles-
terol palmitate, triglycerides and cholesterol, respect-
ively, using a computing densitometer.
Immunohistochemical analysis
Hearts were obtained from human transplant operations.
Immediately after surgical excision, myocardium was cut
in appropriated blocks. Myocardial tissues were immersed
in fixative solution (4 % paraformaldehyde), embedded in(A)
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Figure 1 LRP1, VLDLR and LDLR mRNA expression in control and ICM
reagent and RNA isolated as explained in Methods. LRP1 (A), LDL receptor
PCR. Data were processed with a specially designed software program bas
endogenous control. *P< 0.05 versus CNT. CNT, controls; ICM, ischemic cardparaffin, cut into 5 μm thick serial sections and placed on
poly-L-lysine coated slides. The primary antibodies were
rabbit monoclonal anti-LRP1 (Epitomics 2703 dilution
1:100), mouse monoclonal anti-Troponin T (Thermo sci-
entific MS-295, dilution 1:100) and mouse monoclonal
anti-HIF-1α (Novus NB100-105, dilution 1:50). Antigen
retrieval was required before performing immunohisto-
chemical staining of Troponin T and HIF-1α. In a set of
experiments, before incubation with primary antibody
(2 hours), sections were washed and endogenous perox-
idase activity suppressed with H2O2. Non-specific bind-
ing was blocked with an appropiate serum. The primary
antibodies were detected using the avidin-biotin immuno-
peroxidase technique. The sections were incubated with
an appropriate biotinylated secondary antibody (1:200,
VectorW). 3,3’-diaminobenzidine-haematoxylin chromogen
was used for nuclear stain. The images were captured by
Nikon Eclipse 80i microscope and digitized by Retiga
1300i Fast camera. Magnification (240X).
In other set of experiments, cryosections were subse-
quently incubated with a Cy3-conjugated secondary
antibody (Jackson Immuno Research Laboratories) at
37 °C for 1 h. Slices were finally counterstained for
10 min with Hoechst 33342 (Sigma), and analyzed under
a TCS SP5 confocal microscope (Leica).0
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(B) and VLDLR (C) mRNA expression levels were analyzed by real time
ed on Ct values of each sample and normalized to 18srRNA as
iomyopathy patients.
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Figure 2 LRP1, VLDLR and LDLR protein levels in control and ICM hearts. Representative Western blot analysis (A) showing LRP1, VLDLR,
HIF-1α, VEGF, LDLR and troponin T protein expression in three controls and three ICM patients. Bar graphs showing the mean± SD of protein
LRP1 (B), VLDLR (C), HIF-1α (D) and LDLR (E) band quantification. Unchanged levels of β-actin were shown as loading control and used to
normalize protein bands. *P< 0.05 versus CNT. CNT, controls; ICM, ischemic cardiomyopathy patients.
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Results are expressed as mean ± standard deviation (SD).
Statistical significance between groups was analyzed by
one-way analysis of variance (ANOVA) followed by a
post-hoc Tamhane test. Correlation analysis was per-
formed according to Pearson. Statistics were calculated
using Statistical software package Statview (SPSS) for
Windows. A value of P < 0.05 was considered significant.
Results
Clinical characteristics of patients
The clinical and echocardiographic characteristics of
patients are summarized in Table 1. These patients were
all symptomatic, had a NYHA functional classification
of III-IV and were previously diagnosed with significant
comorbidities including hypertension, hypercholesterol-
emia, obesity, and diabetes mellitus. Patients (93 %) were
mostly men with a mean age of 54.53±2.67 years andTroponin T
HIF-1
LRP1
CNT
α
Figure 3 LRP1, HIF-1α and troponin T staining in control and ICM hea
(panel a & d), HIF-1α (panel b & e) and troponin T (panel c & f) staining in
ischemic cardiomyopathy. Magnification x 240.had at least one vessel affected by atherosclerosis. Left
ventricular end-diastolic diameter was 67.00 ± 2.45. Eight
non-diseased donor hearts were used as control (CNT)
(60 % male, mean age 55±3 years, and EF > 50 %). A high
percentage of patients (67 %) were subjected to reperfu-
sion techniques, also indicative of peri-infarct ischemia.
Myocardial lipoprotein receptor expression
LRP1 expression was analyzed at mRNA level by real
time PCR and at the protein level by Western blot ana-
lysis from the same sample. As shown in Figure 1A,
LRP1 mRNA expression was significantly higher in
ICM than in control group (ICM: 20.57±12.41 vs CNT:
10.66±1.13, P < 0.05). In contrast, LDLR mRNA expres-
sion (Figure 1B) was significantly lower in ICM com-
pared to controls (ICM: 1.89±1.29 vs CNT: 11.14±10.90,
P < 0.05). No differences were found in VLDLR mRNA
expression between controls and ICM hearts (Figure 1C).ICM
(A)
(C)
(B)
(D)
(E)
(F)
rts. Representative immunohistochemical analysis of LRP1
consecutive slides of CNT and ICM samples. CNT, controls; ICM,
ICMCNT
Figure 4 Confocal microscopy analysis of LRP1 expression in control and ICM hearts. Representative confocal microscope images showing
specific LRP1 detection in myocardium from one ICM patient subjected to reperfusion and one from a control subject. Nuclei were
counterstained with Hoechst 33342 (blue). Scale bars = 50 μm (magnification x 400).
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http://www.translational-medicine.com/content/10/1/160In agreement with real-time PCR data, Western blot ana-
lysis showed that LRP1 protein expression was signifi-
cantly higher in ICM than in CNT hearts (ICM:
30.62 ± 13.93 vs CNT: 5.92 ± 0.66, P < 0.05) (Figure 2A &
B). Additionnally, VLDLR protein expression was signifi-
cantly upregulated in ICM compared to CNT samples
(ICM: 15.48 ± 10.62 vs CNT: 3.68 ± 2.98, P < 0.05)
(Figure 2A & C). In order to know whether HIF-1α tran-
scription factor may play a role on lipoprotein receptor
upregulation in ICM samples, we analyzed HIF-1α0
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Figure 5 Dose-dependent changes of LRP1 protein levels in cardiomy
conditions. HL-1 cardiomyocytes were submitted to normoxia or hypoxia
(A) or LDL (B) for the last 12 hours. Representative Western blot analysis sh
loading control and used to normalize LRP1 bands. Results were shown as
duplicate.*P< 0.05 versus normoxic cells. # P< 0.05 versus cells incubated inprotein levels by Western blotting and used VEGF as a
positive control. HIF-1α protein levels were significantly
higher in ICM in comparison with CNT hearts (ICM:
12.63 ± 2.92 vs CNT: 5.11 ± 1.97, P < 0.05) (Figure 2A &
D), as well as VEGF significantly increased in ICM sam-
ples. In contrast to LRP1 and VLDLR, LDLR protein ex-
pression was significantly lower in ICM samples
(Figure 2A & E).
Immunohistochemical analysis (Figure 3A) showed
that LRP1 (panel a) and HIF-1α (panel b) staining were0
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Figure 6 Role of LRP1 in the uptake of modified lipids by
cardiomyocytes. Control and LRP1-deficient HL-1 cardiomyocytes
were submitted to or hypoxia for 24 hours either in absence or
presence of nLDL or agLDL (0.6 mM) for the last 12 hours. Cells
were exhaustively washed and collected in NaOH 0.1 M as
explained in Methods. Thin layer chromatography showing CE
and FC bands and histograms with their quantification. Results
are expressed as micrograms per milligram of protein and
shown as mean ± SEM of three experiments performed in
triplicate. ξP< 0.05 versus control cells.
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trary, there was a positive staining for LRP1 (panel d)
and HIF-1α (panel e) in the myocardium of ICM
patients. Confocal microscopy showed higher cardio-
myocyte LRP1 staining in ICM patients compared to
control subjects (Figure 4).
Effect of VLDL and LDL on LRP1 protein expression in
cardiomyocytes under normoxic and hypoxic conditions
VLDL (1.8 mM) (Figure 5A) and LDL (2.6 mM)
(Figure 5B) significantly increased LRP1 protein by 1.72-
fold and 2-fold, respectively. Hypoxia per se also exerted
a significant upregulatory effect on LRP1 expression in
HL-1 cardiomyocytes in agreement with previous results
[17]. Previous studies from our group showed that LRP1
play a key role for aggregated LDL (agLDL) uptake in
human vascular smooth muscle cells [21-23]. To know
whether LRP1 may also take modified lipids in cardio-
myocytes, we exposed control and LRP1-deficient cardi-
omyocytes [17] to agLDL. As shown in Figure 6, LRP1
deficiency significantly decreased the strong intracellular
CE accumulation (65 ± 3 μg CE/mg protein) derived
from agLDL (0.6 mM) in HL-1 cardiomyocytes. In con-
trast, LRP1 deficiency did not influence the slight intra-
cellular CE (10.6 ± 0.2 μg CE/mg protein) induced by
native LDL (0.6 mM) in cardiomyocytes.
Myocardial neutral lipid content and correlation with
lipoprotein receptor expression
Myocardial lipid content was analyzed by thin layer
chromatography following lipid extraction. Figure 7 shows
representative CE, TG and FC bands from ICM patients
and controls. Both myocardial CE (ICM: 92.2±68.3 vs
CNT: 39±18, P < 0.05) and TG (ICM: 100.2±44.4 vs
CNT: 50.8±39.4, P= 0.04) content was significantly
increased in ICM vs CNT. FC content of myocardium
was unaltered by disease.
Myocardial CE strongly correlated with LRP1 mRNA
(R2 = 0.74, P < 0.0001) (Figure 8A) and LRP1 protein ex-
pression (R2 = 0.72, P < 0.0001) (Figure 8B). Although to
a minor extent, myocardial CE also correlated with
VLDLR protein expression (R2 = 0.398, P < 0.012). In
contrast, myocardial TG content did not show any cor-
relation with LRP1 mRNA or protein expression.
Discussion
Taken together, our results demonstrate for the first time
that myocardial LRP1 expression and cholesteryl ester
content appear strongly increased and interrelated in the
myocardium of ischemic cardiomyopathy patients. In
particular, we show that LRP1 is upregulated in ischemic
human hearts at mRNA and protein levels, although to
a different extent. This difference in the quantitative
modulation of LRP1 at mRNA and protein levels byhypoxia has been previously shown in human VSMC
and it may be explained at least in part by the long half-
life time of LRP1 protein [18].
The upregulation of HIF-1α protein levels in ICM
hearts suggests that in patients, as previously shown in
cultured cardiomyocytes [17] and vascular cells [18],
HIF-1α may participate in myocardial LRP1 upregulation
in ischemic hearts. However, further studies are required
to know the precise role of HIF-1α on myocardial LRP1
overexpression in ischemic cardiomyopathy. In the
group of patients included in this study, there was a high
percentage of those with documented perfusion abnor-
malities, indicative of peri-infart ischemia. Moreover,
enrolled patients had at least one vessel affected by ath-
erosclerosis. Therefore, cardiovascular risk factor such
as hypercholesterolemia or hypertension likely modu-
late LRP1 expression in the myocardium, as previously
reported by our group in the vascular wall [19,24-26].
Indeed, the presented results demonstrate that high
VLDL and LDL dose strongly increased LRP1 protein
levels in cardiomyocytes.
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http://www.translational-medicine.com/content/10/1/160Ischemia has been reported to upregulate VLDLR ex-
pression in cultured cardiomyocytes [12,16] and mice
[16]. We also found VLDLR protein overexpressed in a
porcine model of acute myocardial infarction [17] and in
human ischemic hearts. Although VLDLR has been
reported to be upregulated at mRNA level in myocardial
biopsies taken from patients scheduled for coronary by-
pass surgery [16], we did not observe alterations of
mRNA VLDLR expression levels in explanted hearts
from ICM patients. It has been previously suggested that
cyclosporine, an immunosuppressant used for the treat-
ment of transplant recipients, inhibits VLDLR mRNA
expression in the myocardium of ischemic cardiomyop-
athy patients [16]. In contrast to LRP1 expression, LDLR
mRNA expression was lower in ischemic heartsP<0.0001
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Figure 8 Correlation between LRP1 and CE content in the myocardiu
between myocardial cholesteryl ester content and LRP1 mRNA (A) or LRP1compared to controls in agreement with our previous
results in hypoxic cardiomyocytes [12,17] and vascular
cells [18], suggesting that the classical LDLR plays no
role in the neutral lipid accumulation associated to is-
chemic myocardium.
A significant finding of this study is the close associ-
ation between LRP1 expression and cholesteryl ester ac-
cumulation in ischemic human hearts. Although this
study does not provide information about the mechan-
isms involved in the link between LRP1 expression and
CE accumulation, previous studies in our group have
shown that LRP1 plays an essential role in the selective
VLDL-cholesteryl ester uptake by hypoxic cardiomyo-
cytes [17]. Additionnally, results from the present study
show that cardiomyocyte LRP1, as vascular LRP1 [21-23],P<0.0001
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http://www.translational-medicine.com/content/10/1/160internalizes cholesteryl esters from modified lipopro-
teins. Taken together, these results support that CE over-
accumulation in human ischemic hearts may be caused
by the capacity of LRP1, when overexpressed by hypoxia,
to take up cholesterol from lipoproteins. Previously, it
has been shown that increased expression of VLDLR is
essential for the accumulation of triglycerides in hypoxic
cardiomyocytes and ischemic myocardium in mice [16].
These authors also found a slight but significant cor-
relation between VLDLR mRNA and ORO staining.
Here, we found that VLDLR, although to a minor extent
that LRP1 expression, also correlated with CE accumu-
lation in ischemic heart. In contrast, we did not observe
any significant correlation between LRP1 or VLDLR
expression and myocardial TG content. This lack of cor-
relation may be related to the multiple pathways that
influence myocardial TG content, that may derive from
endogenous synthesis [27,28], diffusion of albumin-
associated fatty acids [29] or lipoprotein-TG-hydrolysis
by LpL [30,31].
In addition, also in agreement with our previous stud-
ies in vitro [12,17] and in vivo [17], we evidenced that in
the myocardium of ischemic cardiomyopathy patients
there was not only triglyceride but also cholesteryl ester
accumulation. This is an interesting observation since
most of the previous studies assumed that myocardial
neutral lipid accumulation consist only in triglycerides
[1-3,16]. Indeed, a precise knowledge about the mechan-
ism of myocardial lipid uptake is required to prevent the
deleterious consequences of this process in cardiac
functionality.
Limitations and considerations of the study
The complexity of cardiomyopathy and heart failure
originated by myocardial infarction cannot be afforded
by testing the effect of hypoxia (1 % O2) in cultured
cardiomyocytes or the effect of coronary occlusion on
porcine myocardial gene expression. However, these
in vitro and in vivo models have been useful to identify
new genes involved in pathophysiological mechanisms
underlying the deleterious effect of hypoxia on cardiac
function. Recently, our group has previously identified
LRP1 as key receptor for cholesteryl ester accumulation
in hypoxic cardiomyocytes and ischemic porcine myo-
cardium [17]. Results from the present study show that
there is a strong LRP1 upregulation that significantly
correlates with cholesteryl ester accumulation in ische-
mic cardiomyopathy patients. Therefore, our results
suggest that cardiac alterations associated to the dele-
terious effects of myocardial cholesterol accumulation
may be modulated through LRP1 targeting in heart
failure and cardiomyopathy.
The clinical consequences of lipid accumulation under
ischemia have not been directly addressed in this studybut it is known that there is a close association between
CE content of sarcoplasmatic reticulum and SERCA-2
suppression [32]. Additionally, hypercholesterolemia
exacerbates myocardial necrosis and apoptosis in the
setting of ischemia-reperfusion [33]. It is also known that
hypoxia exerted a downregulatory effect on SERCA2 ex-
pression through HIF-1α [34]. Our group demonstrated
that hypoxia exacerbates the alterations in calcium hand-
ling induced by VLDL through potentiation of SERCA2
downregulation [12], and that the percentage of waves
was reduced in calcium-overloaded-LRP1-deficient cardi-
omyocytes under stimulation. Taken together, our results
consistently point out that LRP1 is a potential molecular
target to prevent myocardial CE accumulation, and thus
the cardiac alterations induced by cholesterol loading in
ischemic cardiomyopathy.
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